INTELLIA THERAPEUTICS INC (NTLA)
Health Care · CRISPR-based gene editing / genome medicines · NASDAQ
CRISPR-based genome editing company developing in vivo therapies for rare genetic diseases including hereditary angioedema and ATTR amyloidosis.
What INTELLIA THERAPEUTICS INC does
Intellia Therapeutics is a clinical-stage biopharmaceutical company focused on developing in vivo CRISPR genome editing therapies. The company's lead program, lonvoguran ziclumeran (lonvo-z / NTLA-2002), is a one-time treatment candidate for hereditary angioedema (HAE) with Phase 3 data expected in mid-2026 and potential U.S. launch in H1 2027. Its second major program, nexiguran ziclumeran (nex-z / NTLA-2001), targets transthyretin (ATTR) amyloidosis, with Phase 3 trials ongoing following FDA clinical hold resolution.
Themes: ["CRISPR / genome editing","rare genetic diseases","hereditary angioedema (HAE)","ATTR amyloidosis","in vivo therapeutics"]
Fundamentals
- Price$15.44 as of 2026-07-09 close
- Market cap$2.2B as of 2026-07-10
- 1-year return+27.3% as of 2026-07-09 close
- Net margin-597.0% as of 2026-07-10
- ROE-57.3% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)+45.0% as of 2026-07-10
- Revenue CAGR (3y)+9.1% SEC XBRL
- Beta1.76 as of 2026-07-10
Key risks (from latest filing)
["Clinical development risk: FDA clinical holds were placed on MAGNITUDE and MAGNITUDE-2 Phase 3 trials for nex-z; successful resumption and completion are not assured, and Phase 3 lonvo-z data in mid-2026 may not support regulatory approval or commercial launch timelines.","Regulatory and manufacturing risk: Ability to successfully file and obtain regulatory approval for lonvo-z BLA by H2 2026 is uncertain; manufacturing and material sourcing challenges could impact clinical or commercial supply.","Capital requirements and financing risk: Company is unprofitable with negative 597% net margin; funding needs extend at least through 2028, and ability to raise additional capital or establish favorable partnerships is not guaranteed."]
Competitors & peers
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.